Next Article in Journal
The Role of the Nurse in Informed Consent to Treatments: An Observational-Descriptive Study in the Padua Hospital
Previous Article in Journal
Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia
Article

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature

1
Department of Medical Oncology, King Fahad Specialist Hospital, Dammam 31444, Saudi Arabia
2
Department of Internal Medicine, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia
3
Oncology Centre, King Abdullah Medical City, Makkah 24246, Saudi Arabia
4
College of Medicine, Umm Al-Qura University, Makkah 24211, Saudi Arabia
5
Oncology Department, King Abdulaziz Medical City, Riyadh 11426, Saudi Arabia
6
King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia
7
Department of Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi 999041, United Arab Emirates
8
Emirates Oncology Society, Dubai 22107, United Arab Emirates
9
College of Medicine, University of Sharjah, Sharjah 999041, United Arab Emirates
10
Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam 31444, Saudi Arabia
*
Author to whom correspondence should be addressed.
Academic Editor: Anna Capasso
Clin. Pract. 2021, 11(3), 467-471; https://doi.org/10.3390/clinpract11030062
Received: 22 May 2021 / Revised: 13 June 2021 / Accepted: 24 June 2021 / Published: 27 July 2021
Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities to standard dose 5-FU based chemotherapy. DPYD gene sequencing revealed rare different polymorphisms that prompted dose adjustments of administered 5-FU and capecitabine. To our knowledge, this is the first case series looking at DPYD polymorphisms in the Saudi Arabian population. View Full-Text
Keywords: dihydropyrimidine dehydrogenase; 5-Fluorouuracil; chemotherapy; DPYD; polymorphism dihydropyrimidine dehydrogenase; 5-Fluorouuracil; chemotherapy; DPYD; polymorphism
MDPI and ACS Style

Bukhari, N.; Alshangiti, A.; Tashkandi, E.; Algarni, M.; Al-Shamsi, H.O.; Al-Khallaf, H. Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature. Clin. Pract. 2021, 11, 467-471. https://doi.org/10.3390/clinpract11030062

AMA Style

Bukhari N, Alshangiti A, Tashkandi E, Algarni M, Al-Shamsi HO, Al-Khallaf H. Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature. Clinics and Practice. 2021; 11(3):467-471. https://doi.org/10.3390/clinpract11030062

Chicago/Turabian Style

Bukhari, Nedal, Abdulraheem Alshangiti, Emad Tashkandi, Mohammed Algarni, Humaid O. Al-Shamsi, and Hamoud Al-Khallaf. 2021. "Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature" Clinics and Practice 11, no. 3: 467-471. https://doi.org/10.3390/clinpract11030062

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop